Clevidipine overdosage

Revision as of 19:23, 27 February 2014 by ShiSheng (talk | contribs) (Created page with "__NOTOC__ {{Clevidipine}} {{CMG}}; {{AE}} {{SS}} ==Overdosage== There has been no experience of overdosage in human clinical trials. In clinical trials, doses of Cleviprex u...")
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search
Clevidipine
CLEVIPREX® FDA Package Insert
Indications and Usage
Dosage and Administration
Dosage Forms and Strengths
Contraindications
Warnings and Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Overdosage
Description
Clinical Pharmacology
Nonclinical Toxicology
Clinical Studies
How Supplied/Storage and Handling
Patient Counseling Information
Labels and Packages
Clinical Trials on Clevidipine
ClinicalTrials.gov

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sheng Shi, M.D. [2]

Overdosage

There has been no experience of overdosage in human clinical trials. In clinical trials, doses of Cleviprex up to 106 mg/hour or 1153 mg maximum total dose were administered. The expected major effects of overdose would be hypotension and reflex tachycardia.

Discontinuation of Cleviprex leads to a reduction in antihypertensive effects within 5 to 15 minutes [see Clinical Pharmacology (12.2)]. In case of suspected overdosage, Cleviprex should be discontinued immediately and the patient’s blood pressure should be supported.[1]

References

  1. "CLEVIPREX (CLEVIDIPINE) EMULSION [THE MEDICINES COMPANY]". Retrieved 27 February 2014.

Template:Calcium channel blockers